Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Elsevier Science
      Original Publication: Oxford, New York [etc.] Paragamon Press.
    • Subject Terms:
      Neutrophils/*drug effects ; Neutrophils/*metabolism ; Oxazoles/*pharmacology ; Receptors, Formyl Peptide/*agonists ; Receptors, Formyl Peptide/*metabolism ; Receptors, Lipoxin/*agonists ; Receptors, Lipoxin/*metabolism ; Signal Transduction/*drug effects ; Triazoles/*pharmacology; Cells, Cultured ; Dose-Response Relationship, Drug ; Humans ; Oxazoles/chemistry ; Signal Transduction/physiology ; Triazoles/chemistry
    • Abstract:
      Despite the steadily increased numbers of formyl peptide receptor (FPR) ligands identified over the years, few have been characterized in studies using animal disease models and even less have entered clinical trials in human subjects. A small-molecule compound, Act-389949, was however recently tested in a phase I clinical trial and found to be safe and well tolerated in healthy human subjects. The desired anti-inflammatory property of Act-389949 was proposed to be mediated through FPR2, one of the FPRs expressed in neutrophils, but no basic characterization was included in the study. To gain more insights into FPR2 recognition of this first-in-class compound for future utility of the agonist, we have in this study determined the receptor preference and down-stream signaling characteristics induced by Act-389949 in human blood neutrophils isolated from healthy donors. Our data demonstrate that Act-389949 is an agonist for FPR2 that triggers functional/signaling repertoires comparable to what has been earlier described for other FPR2 agonists, including neutrophil chemotaxis, granule mobilization and activation of the NADPH-oxidase. In fact, Act-389949 was found to be as potent as the prototype FPR2 peptide agonist WKYMVM and had the advantage of being resistant to oxidation by MPO-H 2 O 2 -halide derived oxidants, as compared to the sensitive WKYMVM. The down-stream signals generated by Act-389949 include an FPR2-dependent and Gαq-independent transient rise in intracellular Ca 2+ and recruitment of β-arrestin. In summary, our data show that Act-389949 serves as an excellent tool-compound for further dissection of FPR2-regulated activities in vitro and in vivo. Potent and stable FPR ligands such as Act-389949 may therefore be used to develop the next generation of FPR signaling regulating anti-inflammatory therapeutics.
      (Copyright © 2019. Published by Elsevier Inc.)
    • Contributed Indexing:
      Keywords: Balanced agonism; Formyl peptide receptors; NADPH-oxidase; Neutrophils; Receptor agonists; β-Arrestin
    • Accession Number:
      0 (ACT-389949)
      0 (FPR2 protein, human)
      0 (Oxazoles)
      0 (Receptors, Formyl Peptide)
      0 (Receptors, Lipoxin)
      0 (Triazoles)
    • Publication Date:
      Date Created: 20190516 Date Completed: 20200330 Latest Revision: 20200330
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.bcp.2019.04.030
    • Accession Number:
      31085160